DNX 515
Alternative Names: DNX-515Latest Information Update: 28 Sep 2020
At a glance
- Originator DNX Biopharmaceuticals
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Autoimmune disorders; Inflammation
Most Recent Events
- 18 Sep 2020 DNX 515 is available for licensing as of 18 Sep 2020. http://www.dnxbio.com/partnering-licensing.html
- 18 Sep 2020 Early research in Autoimmune disorders in USA (unspecified route) DNX Pharmaceuticals website, September 2020
- 18 Sep 2020 Early research in Inflammation in USA (unspecified route) (DNX Pharmaceuticals website, September 2020)